Home › Trials › NCT06465810

Observing the natural course of transthyretin amyloidosis

A Non-interventional, Prospective, Multi-country Study Collecting Real-world Data on the Characteristics, Treatment Patterns, and Outcomes of Patients With Transthyretin (ATTR) Amyloidosis

AstraZeneca · NCT06465810

This study is looking to see how transthyretin amyloidosis progresses over time in over 1,600 adults while also gathering information on how well treatments like eplontersen work.

Quick facts

Study typeObservational
Enrollment1850 (estimated)
Ages18 Years to 130 Years
SexAll
SponsorAstraZeneca (industry)
Locations60 sites (La Jolla, California and 59 other locations)
Trial IDNCT06465810 on ClinicalTrials.gov

What this trial studies

The MaesTTRo study is an international, longitudinal, non-interventional study that aims to enroll over 1,600 adult patients diagnosed with transthyretin (ATTR) amyloidosis. The study will collect primary data through patient-reported outcome questionnaires and secondary data from routine clinical practices to observe the disease's natural progression and treatment patterns. Patients will be followed for a minimum of 3 years, with data collected during routine visits, ensuring minimal disruption to their care. The study also aims to gather information on the effectiveness of treatments like eplontersen, a gene silencing therapy targeting TTR proteins.

Who should consider this trial

Good fit: Ideal candidates for this study are adults aged 18 and older with a confirmed diagnosis of ATTR amyloidosis who can provide informed consent.

Not a fit: Patients with primary or light chain amyloidosis, asymptomatic ATTR mutation carriers, or those participating in interventional trials for ATTR amyloidosis may not benefit from this study.

Why it matters

Potential benefit: If successful, this study could provide valuable insights into the natural history of ATTR amyloidosis and improve treatment strategies for patients.

How similar studies have performed: While this study employs a novel observational approach, similar studies have shown success in understanding the natural history of other amyloidosis types.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* Patient willing and able to provide written informed consent to participate in the study
* Confirmed diagnosis of amyloid transthyretin (ATTR) amyloidosis
* Aged ≥18 years at the time of signing the informed consent
* Patient willing and able to participate in collection of electronic patient reported outcomes (PROs)

Exclusion Criteria:

* Concurrent participation in any interventional trial for ATTR amyloidosis
* Involvement in the planning and/or conduct of the current study
* Patients with evidence of primary or light chain amyloidosis (AL) or serum protein A amyloidosis (AA)
* Asymptomatic patients with ATTR amyloidosis and asymptomatic ATTR mutation carriers

Where this trial is running

La Jolla, California and 59 other locations

+10 more sites — see ClinicalTrials.gov for the full list.

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.

View on ClinicalTrials.gov →

Conditions: Transthyretin Amyloidosis, ATTR-CM, ATTRv-PN, ATTR, ATTR-Mixed, hATTR, Amyloidosis, Transthyretin

Last reviewed 2026-05-15 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.